Beam Therapeutics Stock Soars on Gene-Editing Buzz – Analysts Project Big Upside

Beam Therapeutics’ stock surged on Monday, Oct. 20, extending a strong upward streak. By mid-afternoon the share price hit $30.35, up 16.8% for the dayfinviz.com. This marked BEAM’s highest price since early 2024 and a dramatic rebound from its summer lows. Traders point to a bullish “golden cross” pattern on Beam’s chart – the stock’s 50-day moving average recently rose above its 200-day averagefinviz.com, a technical signal often seen as confirmation of a positive trend reversal. Zacks noted that BEAM had rallied ~6.8% over the prior four weeks leading into this golden-cross eventfinviz.com, helping shift its Zacks Rank to #2. The sharp Monday jump may have been fueled by momentum traders reacting to these technicals and upbeat analyst commentary, as well as broader sector tailwinds.

Biotechnology · NASDAQ:BEAM · NASDAQ:CRSP · NASDAQ:NTLA · NYSE:LLY · Stock Market
Nasdaq’s Wild Week: Tech Titans Soar & Plunge as Volatility Spikes – What’s Next?

Nasdaq’s Wild Week: Tech Titans Soar & Plunge as Volatility Spikes – What’s Next?

After a roller-coaster week, the Nasdaq Composite Index managed to finish in positive territory, showcasing resilience in the face of multiple risk flare-ups. The index closed Friday at 22,679.98 points, up 117.44 points on the dayreuters.com. All three major U.S. indices posted weekly gains, even as intraday swings tested investors’ nerves. The tech-heavy Nasdaq remains within striking distance of its record high set earlier this month, and is up roughly 15–17% for the year to datets2.tech – a strong performance reflecting 2025’s bullish momentum.
18 October 2025
·········

Eli Lilly (LLY) Surges on Obesity Drug Boom and Alzheimer’s Breakthroughs – Is $1,000 Next?

Eli Lilly’s stock has been on a tear in 2025, powered by optimism around its new drug innovations. Shares surged dramatically at the start of October – leaping from about $726 at the end of September to as high as $832 by October 1ts2.tech. This double-digit jump in just days far outpaced the broader market and reflected euphoric sentiment toward Lilly’s growth prospectsts2.tech. Analysts attributed the rally to a perfect storm of positive news: strong recent earnings, insider buying, and fresh research fueling excitement about Lilly’s obesity and Alzheimer’s franchisests2.tech. For example, one study in late September suggested GLP-1 weight-loss drugs may significantly reduce Alzheimer’s risk, adding to the buzz around Lilly’s pipelinets2.tech.
17 October 2025
··

Eli Lilly Stock Rockets on GLP‑1 Boom and New Approvals: Is LLY the Next Trillion‑Dollar Pharma Titan?

Eli Lilly and Company has become the poster‑child for the emerging class of GLP‑1‑based obesity and diabetes therapies. Its injectable tirzepatide products Mounjaro and Zepbound have delivered explosive growth, propelling the company’s market capitalization into the high‑hundred‑billion range. On 6 Oct 2025, LLY traded around $840, close to its all‑time highsmarketbeat.com. The company’s pivot toward metabolic and neurodegenerative diseases, combined with an aggressive manufacturing expansion, has made it one of the most closely watched stocks on Wall Street.
6 October 2025
·
Shutdown Drags On But Wall Street Hits Records – Here’s What’s Driving Markets

Shutdown Drags On But Wall Street Hits Records – Here’s What’s Driving Markets

Wall Street extended its rally in the face of political gridlock. Last week, the S&P 500 and Dow each rose ~1.1%, and the Nasdaq gained 1.3%, with the S&P and Dow closing at record highs on Friday reuters.com. Monday’s trading opened on a strong note as well – S&P 500 futures were up about 0.3% early in the day, on track to add to those gains reuters.com. “It certainly feels like momentum is on the side of investors over the last few days,” said Mona Mahajan, head of investment strategy at Edward Jones reuters.com. She noted that traders have been increasingly betting on Federal Reserve rate cuts as economic data softens, even with Washington in disarray. The ongoing government shutdown, now past the one-week mark, has not derailed bullish sentiment so far.
6 October 2025
····
Bitcoin Blasts Past $125K, AI Wars Escalate, and Space Tech Soars – Global Tech Roundup (Oct 5–6, 2025)

Bitcoin Blasts Past $125K, AI Wars Escalate, and Space Tech Soars – Global Tech Roundup (Oct 5–6, 2025)

OpenAI vs. Musk’s xAI – legal battle heats up: The Silicon Valley rivalry between Elon Musk and OpenAI turned into open warfare in court. Musk’s AI startup xAI sued OpenAI, accusing it of poaching staff to steal trade secrets related to xAI’s Grok chatbot. This week OpenAI hit back, asking a judge to dismiss the suit and blasting it as part of Musk’s “ongoing harassment” of the company reuters.com. OpenAI’s filing argued that “talented xAI employees are leaving in droves” under Musk and have every right to join OpenAI reuters.com. Musk, a co-founder turned critic of OpenAI, claims xAI’s tech is more advanced than ChatGPT and that OpenAI conspired with Apple to suppress rivals – allegations both Apple and OpenAI deny reuters.com. “The truth is that xAI is hemorrhaging talent to other competitors, including OpenAI,” the filing stated bluntly reuters.com. The feud has become a high-profile drama amid the red-hot AI talent race, with dueling lawsuits reflecting the skyrocketing stakes in generative AI. As one industry commentator put it, this is “CEO-speak for ‘We’re pawns in a digital Cold War’” reuters.com – the AI war is as much personal as technological.
6 October 2025
··········
U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

U.S. Stocks Rally as Shutdown Fears Fade – Markets Hit Fresh Records

Lara Castleton of Janus Henderson noted that Tuesday’s White House–Pfizer announcement “was the catalyst for healthcare,” freeing up investors to rotate into the beaten-down sector reuters.com. Kyle Rodda at Capital.com observed that the weak ADP report “suggests the U.S. economy is in almost dire need for further policy support,” so markets are pricing in much higher odds of Fed rate cuts in October and December reuters.com. He added that “after some initial jitters, markets shrugged off the U.S. government shutdown, at least for now,” since past shutdowns have had “trivial” market impact reuters.com.
2 October 2025
······
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Fed policy: The Fed’s Sept. 17 decision to cut rates was driven by slowing growth and job gains, though inflation has crept up federalreserve.gov. Fed Chair Powell and colleagues signaled further cuts ahead, but warned that inflation upside risks remain high federalreserve.gov reuters.com. Fed Vice Chair Bowman urged a commitment to cuts to shore up jobs reuters.com, while a strategist noted Powell was dovish but noncommittal on timing reuters.com.
28 September 2025
·············
Billion-Dollar AI Bets and Biotech Breakthroughs: Top Tech News (Sept 27–28, 2025)

Billion-Dollar AI Bets and Biotech Breakthroughs: Top Tech News (Sept 27–28, 2025)

Nvidia–OpenAI Partnership: Nvidia announced a landmark collaboration with OpenAI to deploy at least 10 gigawatts of AI computing power. Under the plan, Nvidia will invest up to $100 billion as each gigawatt of NVIDIA systems is deployed nvidianews.nvidia.com. The first 1 GW is slated for late 2026 on Nvidia’s new “Vera Rubin” supercomputer. CEO Jensen Huang said this marks “the next leap forward — deploying 10 gigawatts to power the next era of intelligence” nvidianews.nvidia.com. OpenAI’s Sam Altman emphasized that “everything starts with compute,” and the new chips will fuel AI breakthroughs. This deal comes amid massive demand for AI chips – Nvidia will continue to serve all customers, but the investment ties OpenAI and Nvidia closely together nvidianews.nvidia.com nvidianews.nvidia.com.
28 September 2025
·········
Nasdaq’s Wild Week: AI Mega-Deal Hype, Tariff Turmoil, and Tech Titans on Edge

Nasdaq’s Wild Week: AI Mega-Deal Hype, Tariff Turmoil, and Tech Titans on Edge

After charging to all-time highs on Monday, U.S. tech stocks hit some turbulence to end the week. The Nasdaq Composite Index gained +0.44% on Friday to close around 22,484 reuters.com, helped by a relief rally on in-line inflation data. That advance broke a three-day losing streak for stocks latimes.com. Even so, the Nasdaq Composite fell ~0.7% for the week, while the S&P 500 and Dow also logged modest weekly declines reuters.com reuters.com. This marked the end of a three-week run of gains for the Nasdaq and S&P reuters.com. The Nasdaq-100 index of top-tier tech shares showed a similar pattern – rebounding Friday but finishing slightly lower week-over-week.
27 September 2025
··········
Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)

Wall Street Rebounds: PCE In‑Line, Tariff Shock, and Fed‑Cut Bets — What It All Means (Sept. 26, 2025)

1) The data that mattered: PCE & spendingMarkets exhaled as the Fed’s preferred inflation gauge arrived exactly as expected: headline PCE +0.3% m/m, core +0.2% m/m. Treasury yields drifted lower, with the 10‑yr near 4.18% and the 2‑yr around 3.65%, signaling relief that there was no upside shock. Futures ticked higher on the print. Reuters
26 September 2025
·······
Science Shockers: AI-Created Viruses, “Water Worlds” Debunked & More (Sept 19–20, 2025)

Science Shockers: AI-Created Viruses, “Water Worlds” Debunked & More (Sept 19–20, 2025)

AI Designs New Viruses: In a stunning demonstration of AI’s creative power, scientists announced they have used artificial intelligence to design the first-ever viruses from scratch. The AI wrote complete viral genomes for bacteriophages which were then synthesized in the lab nature.com. Several of these AI-generated phages successfully infected and killed E. coli bacteria that natural phages couldn’t attack nature.com. “This is the first time AI systems are able to write coherent genome-scale sequences,” said Stanford computational biologist Brian Hie, calling it a step toward “AI-generated life” nature.com. While still in preprint and not yet peer-reviewed, the breakthrough suggests AI could become a powerful tool for engineering new biomedical therapies nature.com nature.com. Researchers hope AI-designed phages might one day help fight antibiotic-resistant superbugs nature.com nature.com – showcasing a real-world payoff for AI in medicine. The work also raises biosafety questions, as wholly novel organisms can now be created digitally, underscoring the need for oversight as “the next step is AI-generated life,” in Hie’s words nature.com.
20 September 2025
·····
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly’s forthcoming Richmond-area factory is set to be one of the largest and most advanced pharmaceutical manufacturing sites in the world. At a cost of $5 billion, Lilly will construct a high-tech production campus in Goochland County’s West Creek Business Park, a site that had been prepped for a previous project and now deemed “the perfect spot” for fast construction Washingtonpost. The facility’s core mission: make more of the critical drug ingredients that Lilly usually sources overseas, right here on U.S. soil Washingtonpost Washingtonpost.
16 September 2025
·······
Game-Changing AI Breakthroughs, Big Tech Surprises & Global AI Showdowns (Sept 9–10, 2025)

Game-Changing AI Breakthroughs, Big Tech Surprises & Global AI Showdowns (Sept 9–10, 2025)

One of the week’s most striking research breakthroughs came from Stony Brook University, where scientists unveiled an AI system called SeeMe that can detect “covert consciousness” in patients with acute brain injuries news.stonybrook.edu. In a study of 37 coma patients, SeeMe’s computer vision algorithms analyzed subtle, involuntary facial muscle movements in response to verbal commands, movements so slight they’re invisible to the naked eye news.stonybrook.edu. Remarkably, the tool identified signs of awareness 4–8 days earlier than standard bedside neurological exams news.stonybrook.edu news.stonybrook.edu.
10 September 2025
·····
Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Game-Changing Vaccines, Breakthrough Drugs, and a CDC Shakeup: Biotech & Health News Roundup

Targeted Fall Boosters, But Access Tightened: U.S. health authorities approved new monovalent COVID-19 vaccines updated for the 2025–26 season reuters.com. Unlike prior booster rollouts, the FDA restricted under-65 eligibility to those with risk factors, aligning with guidance from HHS Secretary Robert F. Kennedy Jr., a longtime vaccine skeptic reuters.com. The change marks a sharp departure from broad eligibility in previous years. Officials and experts voiced concern that narrowing access could sow confusion over insurance coverage and leave many younger adults unprotected reuters.com reuters.com. Notably, the FDA also rescinded emergency authorization for Pfizer’s vaccine in children under 5, effectively pausing toddler immunizations reuters.com. Medical societies pushed back – the Infectious Diseases Society of America announced it is working with other groups on independent COVID vaccine guidelines, expected in September reuters.com. The American Academy of Pediatrics even went against federal policy, recommending that all young children get vaccinated for COVID-19 reuters.com.
28 August 2025
····
Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Breakthrough Drugs, Big Deals & Public Health Alerts – Biotech and Health News Roundup (Aug 22–23, 2025)

Sources: Ionis HAE drug approval pharmexec.com biopharmadive.com; BioPharmaDive on Dawnzera pricing and positioning biopharmadive.com biopharmadive.com; AbbVie Rinvoq AA trial via FiercePharma fiercepharma.com; Lancet Neurology SAPPHIRE trial results neurologylive.com neurologylive.com; Reuters – Kite/Gilead’s Interius acquisition reuters.com and Interius press release interiusbio.com; PharmExec on XOMA-Mural deal ts2.tech; Reuters – J&J $2B NC facility and quote ts2.tech ts2.tech; Reuters – Apollo Hospitals stake sale ts2.tech; BiopharmaTrend on Kyorin adopting Elix AI platform biopharmatrend.com biopharmatrend.com; Laotian Times – Amgen Golden Ticket and quote ts2.tech ts2.tech; Allos Pharma press release on arbaclofen rights & Dr. Carpenter quote allospharma.com allospharma.com; Allos press – ASD trial results allospharma.com; BiopharmaDive on VC funding and Kriya Therapeutics raise ts2.tech; Neurology Live – Hearing aids & dementia study ts2.tech ts2.tech; NIH news – Phantom limb cortical maps ts2.tech ts2.tech; WHO/UN joint release – Gaza famine declaration who.int; WHO/WMO report on heat stress who.int; Drug Target Review – Chikungunya outbreak global spread drugtargetreview.com drugtargetreview.com; KFF Health News/Washington Post – CDC layoffs & HHS staff letter kffhealthnews.org kffhealthnews.org.
23 August 2025
·······
1 … 11 12 13 14
Follow on Google News
Add as preferred source Open in Google News